/ Corporate News

Partner Facility Now Growing Canadian Cannabis Strains

VANCOUVER, BC, — (September 28, 2022) – Isracann Biosciences Inc. (CSE: IPOT) (XFRA: A2PT0E) (OTC: ISCNF) (the “Company”) a multi-faceted Israel-based company focused on becoming a premier low cost, high quality cannabis producer/distributor is pleased to announce that previously shipped genetics have cleared Israeli customs and are being raised as mother stock.  

“The Israeli market will now have access to premium Canadian high THC genetics,” notes CEO Phil Floucault. “The three strains we shipped are called: Liberty Haze, Hell Monkey, and Grape Stomper. All three strains have received a positive response from consumers in Canada and I am looking forward to being able to make them available to the Israeli market.”

The three strains sent were developed as part of United Greeneries’ “Grass Roots” genetics program, the goal of which is to produce novel high THC strains with commercially high yields. Currently being sold as premium cannabis flower in Canada, the three strains represent some of the top preforming genetics in United Greeneries’ catalogue. With the support of United Greeneries and Isracann, all three strains have been integrated into the Intelicanna facility and are being prepared as the initial Israeli mother stock.

Phil Floucault continues, “The planning and preparation by the teams in Canada and Israel made this genetics shipment happen smoothly. The growing teams are now fully engaged and working to expedite the process of scaling to full production. In the near term, Canadian quality cannabis will be grown in Israel and available to Israeli customers. Canadian genetics, Israeli grown.”

On Behalf of The Board of Directors

“Phil Floucault”

Phil Floucault
Chief Executive Officer and President

About Isracann Biosciences Inc. (CSE: IPOT) (XFRA: A2PT0E) (OTC: ISCNF)

Isracann is a multidisciplinary cannabis focused producer and product developer with Israeli-based cannabis production farm assets and a Canadian natural health medicine development and production arm. Concurrently focused on initial retail sales in Canada and in becoming a premier cannabis producer offering low-cost domestic Israeli production, the Company aims to commercialize natural health medicines in Canada and to leverage agreements within Israel for import/export opportunities and medicinal marijuana cultivation. For more information visit: www.isracann.com.

Empire Communications Group
+1 (604) 343-2724

Forward-Looking Information

This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “should” occur. Forward-looking statements may include, without limitation, statements relating to the commercial production of Liberty Haze, Hell Monkey and Grape Stomper for the Israeli market. The forward-looking statements contained in this press release are expressly qualified in their entirety by this cautionary statement. All forward-looking statements in this press release are made as of the date of this press release. The forward-looking statements contained herein are also subject generally to assumptions and risks and uncertainties that are described from time to time in the Company’s documents filed from time to time with the CSE, the British Columbia Securities Commission, the Alberta Securities Commission, and the Ontario Securities Commission. Although Isracann believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in forward looking statements. Isracann expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

The CSE does not accept responsibility for the adequacy or accuracy of this release.